(Tiper Stock Exchange) – Svas Biosanaa company listed on Euronext Growth Milan and active in the production of medical devices for healthcare facilities, closed the 2022 with revenues equal to 97.2 million euros, with an increase of 19.9% compared to 31 December 2021. These revenues do not include those generated by the Bormia group (acquired with effect from 1 July 2022) in the period from January to June 2022, amounting to 6.5 million euros.
L’EBITDA amounted to 11.9 million, an increase of 11.7%, with a EBITDA margin 12.2% of revenues. L’Net income is positive for 3.6 million (up 13% compared to 3.2 million in 2021). The Net Financial Position is cash negative for 21.7 million, compared to the cash negative NFP of 17 million as at 31 December 2021, with the figure affected by the acquisition of Bormia.
“Fiscal year 2022 was a very challenging year for the group due to the well-known geopolitical events, the generalized increase in costs and the difficulties associated with the supply chain – commented theCEO Umberto Perillo – Despite this, we closed a very positive year which saw the group’s growth trend consolidate with revenues registering a 20% increase compared to 2021″.
“The result is the result of commercial and industrial strategy based on the development of strategic markets for us, on innovation, on the enrichment of the product portfolio and on the optimization of all company resources – he added – To obtain such positive results in a difficult and objectively penalizing context, the maximum effort was required of all the employees and collaborators of the group, to whom my personal thanks go”.